These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12812387)

  • 1. Ineffectiveness of measuring routine vital signs in adult inpatients with deep venous thrombosis.
    Potti A; Panwalkar A; Hebert B; Sholes K; Lewis MJ; Hanley J
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):163-6. PubMed ID: 12812387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffectiveness of the measurement of 'routine' vital signs for adult inpatients with community-acquired pneumonia.
    Mariani P; Saeed MU; Potti A; Hebert B; Sholes K; Lewis MJ; Hanley JF
    Int J Nurs Pract; 2006 Apr; 12(2):105-9. PubMed ID: 16529596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vital signs.
    Lockwood C; Conroy-Hiller T; Page T
    JBI Libr Syst Rev; 2004; 2(6):1-38. PubMed ID: 27820007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
    Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
    LaMori JC; Shoheiber O; Mody SH; Bookhart BK
    Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and health costs impact of progress in diagnosis and treatment in venous thromboembolic disease: evolution in 15 years.
    Vera-Arroyo B; Linares-Palomino JP; Lozano-Alonso S; Moreno-Villalonga JJ; Bravo-Molina A; Ros-Die E
    Ann Vasc Surg; 2013 Nov; 27(8):1162-8. PubMed ID: 23953665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients.
    Schwarz T; Schmidt B; Beyer J; Schröder HE; Schellong SM
    J Vasc Surg; 2001 Dec; 34(6):1065-70. PubMed ID: 11743562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internal jugular, subclavian, and axillary deep venous thrombosis and the risk of pulmonary embolism.
    Major KM; Bulic S; Rowe VL; Patel K; Weaver FA
    Vascular; 2008; 16(2):73-9. PubMed ID: 18377835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism risk among hospitalized patients: magnitude of the risk is staggering.
    Goldhaber SZ
    Am J Hematol; 2007 Sep; 82(9):775-6. PubMed ID: 17626256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year outcome study of deep vein thrombosis in the lower limbs.
    Asbeutah AM; Riha AZ; Cameron JD; McGrath BP
    J Vasc Surg; 2004 Dec; 40(6):1184-9. PubMed ID: 15622373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis.
    Ouriel K; Kaul AF; Leonard MC
    J Vasc Surg; 2004 Nov; 40(5):971-7. PubMed ID: 15557913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of isolated soleal and gastrocnemius vein thrombosis.
    Sales CM; Haq F; Bustami R; Sun F
    J Vasc Surg; 2010 Nov; 52(5):1251-4. PubMed ID: 20630686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vital signs--the six-minute warnings.
    McCarthy FM
    J Am Dent Assoc; 1980 May; 100(5):682-91. PubMed ID: 6154071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Pharmacomechanical Endovascular Intervention for Iliofemoral Vein Thrombosis Compared to Conventional Anticoagulation Therapy.
    Kim IS; Jo WM
    J Korean Med Sci; 2017 Jan; 32(1):47-53. PubMed ID: 27914131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Routine are Routine Vital Signs?
    McDaniel LM; Ralston SL
    Hosp Pediatr; 2022 Jul; 12(7):e235-e238. PubMed ID: 35757931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional outcome of individuals with traumatic brain injury and lower extremity deep venous thrombosis.
    Wagner RH; Cifu DX; Keyser-Marcus L
    J Head Trauma Rehabil; 1999 Dec; 14(6):558-66. PubMed ID: 10671701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
    Mantovani LG; Haas S; Kreutz R; Folkerts K; Gebel M; Monje D; Schneider J; van Eickels M; Sahin K; Zell E; Ageno W; Turpie AGG
    Eur J Intern Med; 2019 Mar; 61():29-33. PubMed ID: 30342973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.